{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:57:54Z","timestamp":1770350274628,"version":"3.49.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00277-021-04576-y","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T15:03:21Z","timestamp":1624287801000},"page":"713-715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reduced bendamustine for elderly patients with follicular lymphoma"],"prefix":"10.1007","volume":"101","author":[{"given":"Yosuke","family":"Masamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arika","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-2422","authenticated-orcid":false,"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"issue":"7","key":"4576_CR1","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1200\/jco.2017.74.1652","volume":"36","author":"S Luminari","year":"2018","unstructured":"Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, Rusconi C, Tarantino V, Tucci A, Vitolo U, Kovalchuk S, Angelucci E, Pulsoni A, Arcaini L, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri AJM, Vallisa D, Marcheselli L, Federico M (2018) Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol 36(7):689\u2013696. https:\/\/doi.org\/10.1200\/jco.2017.74.1652","journal-title":"J Clin Oncol"},{"issue":"14","key":"4576_CR2","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trn\u011bn\u00fd M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377(14):1331\u20131344. https:\/\/doi.org\/10.1056\/NEJMoa1614598","journal-title":"N Engl J Med"},{"issue":"9873","key":"4576_CR3","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/s0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, D\u00fcrk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet (London, England) 381(9873):1203\u20131210. https:\/\/doi.org\/10.1016\/s0140-6736(12)61763-2","journal-title":"Lancet (London, England)"},{"key":"4576_CR4","doi-asserted-by":"publisher","first-page":"100549","DOI":"10.1016\/j.eclinm.2020.100549","volume":"27","author":"S Lamure","year":"2020","unstructured":"Lamure S, Dul\u00e9ry R, Di Blasi R, Chauchet A, Laureana C, Deau-Fischer B, Drenou B, Soussain C, Rossi C, No\u00ebl N, Choquet S, Bologna S, Joly B, Kohn M, Malak S, Fouquet G, Daguindau E, Bernard S, Thi\u00e9blemont C, Cartron G, Lacombe K, Besson C (2020) Determinants of outcome in Covid-19 hospitalized patients with lymphoma: a retrospective multicentric cohort study. EClinicalMedicine 27:100549. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100549","journal-title":"EClinicalMedicine"},{"issue":"9","key":"4576_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/op.20.00241","volume":"16","author":"M-EM Percival","year":"2020","unstructured":"Percival M-EM, Lynch RC, Halpern AB, Shadman M, Cassaday RD, Ujjani C, Shustov A, Tseng YD, Liu C, Pergam S, Libby EN, Scott BL, Smith SD, Green DJ, Gopal AK, Cowan AJ (2020) Considerations for managing patients with hematologic malignancy during the COVID-19 pandemic: the Seattle strategy. JCO Oncology Practice 16(9):571\u2013578. https:\/\/doi.org\/10.1200\/op.20.00241","journal-title":"JCO Oncology Practice"},{"issue":"8","key":"4576_CR6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/s1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD (2016) Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17(8):1081\u20131093. https:\/\/doi.org\/10.1016\/s1470-2045(16)30097-3","journal-title":"Lancet Oncol"},{"issue":"9","key":"4576_CR7","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.3109\/10428194.2015.1012714","volume":"56","author":"A Tedeschi","year":"2015","unstructured":"Tedeschi A, Picardi P, Ferrero S, Benevolo G, Margiotta Casaluci G, Varettoni M, Barat\u00e8 C, Motta M, Gini G, Goldaniga MC, Visco C, Zaja F, Belsito Petrizi V, Ravelli E, Gentile M, Urbano MA, Franceschetti S, Ghione P, Orsucci L, Frustaci AM, Gaidano G, Vitolo U, Morra E (2015) Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstr\u00f6m macroglobulinemia. Leuk Lymphoma 56(9):2637\u20132642. https:\/\/doi.org\/10.3109\/10428194.2015.1012714","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"4576_CR8","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1080\/10428194.2016.1253835","volume":"58","author":"DA Bond","year":"2017","unstructured":"Bond DA, Huang Y, Ruppert AS, Walker AR, Dotson EK, Roddy J, Blum KA, Christian BA (2017) Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose. Leuk Lymphoma 58(7):1589\u20131597. https:\/\/doi.org\/10.1080\/10428194.2016.1253835","journal-title":"Leuk Lymphoma"},{"key":"4576_CR9","doi-asserted-by":"publisher","unstructured":"Yamasaki S, Matsushima T, Minami M, Kadowaki M, Takase K, Iwasaki H (2021) Clinical impact of bendamustine exposure on lymphocytopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study. Ann Hematol 1\u20133. https:\/\/doi.org\/10.1007\/s00277-020-04388-6","DOI":"10.1007\/s00277-020-04388-6"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04576-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04576-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04576-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:19:52Z","timestamp":1744190392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04576-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4576"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04576-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]},"assertion":[{"value":"17 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were following the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Yosuke Masamoto received lecture fees from SymBio Pharmaceutical,\u00a0Nippon\u00a0Shinyaku, Eisai, and Chugai Pharmaceutical.\u00a0Mineo Kurokawa received research funding from Chugai Pharmaceutical, Eisai, and Nippon Shinyaku. Mineo Kurokawa received the advisory fee from Chugai Pharmaceutica. Mineo Kurokawa received the lecture fee from Eisai, Chugai Pharmaceutical, and Nippon Shinyaku.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}